Massachusetts Financial Services Co. MA Has $11.78 Million Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Massachusetts Financial Services Co. MA trimmed its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMRFree Report) by 0.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 462,675 shares of the company’s stock after selling 858 shares during the period. Massachusetts Financial Services Co. MA owned about 0.83% of Kymera Therapeutics worth $11,780,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its position in Kymera Therapeutics by 1.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 306,692 shares of the company’s stock worth $7,808,000 after buying an additional 4,951 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Kymera Therapeutics during the 4th quarter worth approximately $246,000. Russell Investments Group Ltd. increased its position in shares of Kymera Therapeutics by 57.9% during the fourth quarter. Russell Investments Group Ltd. now owns 49,111 shares of the company’s stock valued at $1,250,000 after purchasing an additional 17,999 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Kymera Therapeutics by 2.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,940 shares of the company’s stock valued at $584,000 after purchasing an additional 524 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Kymera Therapeutics by 352.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock valued at $164,000 after purchasing an additional 5,002 shares in the last quarter.

Kymera Therapeutics Stock Down 1.8 %

Shares of KYMR stock opened at $34.95 on Friday. Kymera Therapeutics, Inc. has a 12-month low of $9.60 and a 12-month high of $45.31. The firm has a fifty day moving average of $37.38 and a 200-day moving average of $31.23. The firm has a market capitalization of $2.14 billion, a price-to-earnings ratio of -13.92 and a beta of 2.31.

Kymera Therapeutics (NASDAQ:KYMRGet Free Report) last posted its earnings results on Thursday, May 2nd. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. The firm had revenue of $10.30 million during the quarter, compared to analysts’ expectations of $14.24 million. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The company’s revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.70) earnings per share. Research analysts expect that Kymera Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Bruce Booth sold 71,764 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $40.46, for a total value of $2,903,571.44. Following the transaction, the director now owns 806,697 shares of the company’s stock, valued at $32,638,960.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, major shareholder Venture Fund X. L.P. Atlas sold 115,090 shares of the stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $42.23, for a total transaction of $4,860,250.70. Following the completion of the transaction, the insider now directly owns 4,676,075 shares in the company, valued at $197,470,647.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bruce Booth sold 71,764 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $40.46, for a total value of $2,903,571.44. Following the completion of the sale, the director now owns 806,697 shares in the company, valued at approximately $32,638,960.62. The disclosure for this sale can be found here. In the last three months, insiders sold 427,914 shares of company stock valued at $17,986,347. 15.82% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on KYMR. JPMorgan Chase & Co. boosted their price target on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Oppenheimer dropped their price target on shares of Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating for the company in a research report on Friday, May 3rd. Piper Sandler lifted their target price on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Truist Financial increased their price target on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Wolfe Research assumed coverage on Kymera Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $41.10.

Check Out Our Latest Report on KYMR

Kymera Therapeutics Company Profile

(Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Read More

Institutional Ownership by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.